Skip to main content
Journal cover image

Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.

Publication ,  Journal Article
Zalutsky, MR; Reardon, DA; Pozzi, OR; Vaidyanathan, G; Bigner, DD
Published in: Nucl Med Biol
October 2007

An attractive feature of targeted radionuclide therapy is the ability to select radionuclides and targeting vehicles with characteristics that are best suited for a particular clinical application. One combination that has been receiving increasing attention is the use of monoclonal antibodies (mAbs) specifically reactive to receptors and antigens that are expressed in tumor cells to selectively deliver the alpha-particle-emitting radiohalogen astatine-211 (211At) to malignant cell populations. Promising results have been obtained in preclinical models with multiple 211At-labeled mAbs; however, translation of the concept to the clinic has been slow. Impediments to this process include limited radionuclide availability, the need for suitable radiochemistry methods operant at high activity levels and lack of data concerning the toxicity of alpha-particle emitters in humans. Nonetheless, two clinical trials have been initiated to date with 211At-labeled mAbs, and others are planned for the near future.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Nucl Med Biol

DOI

ISSN

0969-8051

Publication Date

October 2007

Volume

34

Issue

7

Start / End Page

779 / 785

Location

United States

Related Subject Headings

  • Staining and Labeling
  • Radiopharmaceuticals
  • Radioimmunotherapy
  • Nuclear Medicine & Medical Imaging
  • Neoplasms
  • Humans
  • Drug Delivery Systems
  • Astatine
  • Antibodies, Monoclonal
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zalutsky, M. R., Reardon, D. A., Pozzi, O. R., Vaidyanathan, G., & Bigner, D. D. (2007). Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies. Nucl Med Biol, 34(7), 779–785. https://doi.org/10.1016/j.nucmedbio.2007.03.007
Zalutsky, Michael R., David A. Reardon, Oscar R. Pozzi, Ganesan Vaidyanathan, and Darell D. Bigner. “Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.Nucl Med Biol 34, no. 7 (October 2007): 779–85. https://doi.org/10.1016/j.nucmedbio.2007.03.007.
Zalutsky MR, Reardon DA, Pozzi OR, Vaidyanathan G, Bigner DD. Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies. Nucl Med Biol. 2007 Oct;34(7):779–85.
Zalutsky, Michael R., et al. “Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.Nucl Med Biol, vol. 34, no. 7, Oct. 2007, pp. 779–85. Pubmed, doi:10.1016/j.nucmedbio.2007.03.007.
Zalutsky MR, Reardon DA, Pozzi OR, Vaidyanathan G, Bigner DD. Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies. Nucl Med Biol. 2007 Oct;34(7):779–785.
Journal cover image

Published In

Nucl Med Biol

DOI

ISSN

0969-8051

Publication Date

October 2007

Volume

34

Issue

7

Start / End Page

779 / 785

Location

United States

Related Subject Headings

  • Staining and Labeling
  • Radiopharmaceuticals
  • Radioimmunotherapy
  • Nuclear Medicine & Medical Imaging
  • Neoplasms
  • Humans
  • Drug Delivery Systems
  • Astatine
  • Antibodies, Monoclonal
  • 3202 Clinical sciences